Krebs von den Lungen-6 (KL-6) as a diagnostic marker for pulmonary fibrosis: a systematic review and meta-analysis.

[1]  Zhaohui Zheng,et al.  CD147 contributes to SARS-CoV-2-induced pulmonary fibrosis , 2022, Signal Transduction and Targeted Therapy.

[2]  C. Chung,et al.  Baseline serum Krebs von den Lungen-6 as a biomarker for the disease progression in idiopathic pulmonary fibrosis , 2022, Scientific Reports.

[3]  B. Xie,et al.  Krebs von den Lungen‐6 levels in untreated idiopathic pulmonary fibrosis , 2022, The clinical respiratory journal.

[4]  Lingyun Gao,et al.  KL-6 as an Immunological Biomarker Predicts the Severity, Progression, Acute Exacerbation, and Poor Outcomes of Interstitial Lung Disease: A Systematic Review and Meta-Analysis , 2021, Frontiers in Immunology.

[5]  Y. Bhandary,et al.  Inflammatory mediators in various molecular pathways involved in the development of pulmonary fibrosis. , 2021, International immunopharmacology.

[6]  Xiaohua Douglas Zhang,et al.  Krebs Von den Lungen-6 as a predictive indicator for the risk of secondary pulmonary fibrosis and its reversibility in COVID-19 patients , 2021, International journal of biological sciences.

[7]  M. Panteghini,et al.  Prognostic role of Krebs von den Lungen-6 (KL-6) measurement in idiopathic pulmonary fibrosis: a systematic review and meta-analysis , 2021, Clinical chemistry and laboratory medicine.

[8]  A. Mostafa,et al.  Role of Krebs von den Lungen-6 (KL-6) in Assessing Hypersensitivity Pneumonitis , 2021, Tuberculosis and respiratory diseases.

[9]  E. Bargagli,et al.  Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy , 2021, Cancers.

[10]  A. Wells,et al.  Serum markers of pulmonary epithelial damage in systemic sclerosis‐associated interstitial lung disease and disease progression , 2020, Respirology.

[11]  S. Noor,et al.  Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment , 2020, Advances in Therapy.

[12]  E. Bargagli,et al.  Utility of serological biomarker’ panels for diagnostic accuracy of interstitial lung diseases , 2020, Immunologic Research.

[13]  Joyce S Lee,et al.  Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs) , 2020, Annals of the Rheumatic Diseases.

[14]  Jonathan H. Chung,et al.  HRCT evaluation of patients with interstitial lung disease: comparison of the 2018 and 2011 diagnostic guidelines , 2020, Therapeutic advances in respiratory disease.

[15]  W. Roque,et al.  A Tale of Two Proteolytic Machines: Matrix Metalloproteinases and the Ubiquitin–Proteasome System in Pulmonary Fibrosis , 2020, International journal of molecular sciences.

[16]  Xiaofeng Zeng,et al.  Comparative diagnostic efficacy of serum Krebs von den Lungen-6 and surfactant D for connective tissue disease-associated interstitial lung diseases , 2020, Medicine.

[17]  Jinbao Huang,et al.  Diagnostic and prognostic predictive values of circulating KL-6 for interstitial lung disease , 2020, Medicine.

[18]  T. Corte,et al.  Review: Serum biomarkers in idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease - frontiers and horizons. , 2019, Pharmacology & therapeutics.

[19]  Y. Allanore,et al.  Performance of Candidate Serum Biomarkers for Systemic Sclerosis–Associated Interstitial Lung Disease , 2019, Arthritis & rheumatology.

[20]  S. Madala,et al.  New therapeutics based on emerging concepts in pulmonary fibrosis , 2018, Expert opinion on therapeutic targets.

[21]  Y. Yamaguchi,et al.  The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis , 2017, PloS one.

[22]  N. Kohno,et al.  Comparative Study of Circulating MMP-7, CCL18, KL-6, SP-A, and SP-D as Disease Markers of Idiopathic Pulmonary Fibrosis , 2016, Disease markers.

[23]  N. Inase,et al.  The usefulness of KL-6 and SP-D for the diagnosis and management of chronic hypersensitivity pneumonitis. , 2015, Respiratory medicine.

[24]  R. Dunmore,et al.  The epithelium in idiopathic pulmonary fibrosis: breaking the barrier , 2014, Front. Pharmacol..

[25]  Sana Boudabbous,et al.  Computed tomography of the chest with model-based iterative reconstruction using a radiation exposure similar to chest X-ray examination: preliminary observations , 2013, European Radiology.

[26]  M. Maeda,et al.  The elevation of serum napsin A in idiopathic pulmonary fibrosis, compared with KL-6, surfactant protein-A and surfactant protein-D , 2012, BMC Pulmonary Medicine.

[27]  M. Fujimoto,et al.  Use of Serum Clara Cell 16-kDa (CC16) Levels as a Potential Indicator of Active Pulmonary Fibrosis in Systemic Sclerosis , 2011, The Journal of Rheumatology.

[28]  J. Grutters,et al.  CA 15-3 as an alternative marker for KL-6 in fibrotic lung diseases. , 2010, Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG.

[29]  N. Kohno,et al.  Immunohistochemical and immunoelectron microscopic studies of the localization of KL-6 and epithelial membrane antigen (EMA) in presumably normal pulmonary tissue and in interstitial pneumonia , 2007, Medical Molecular Morphology.

[30]  Shinichi Sato,et al.  Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. , 2004, The Journal of rheumatology.

[31]  H. Ihn,et al.  Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis. , 2000, The Journal of rheumatology.

[32]  N. Kohno,et al.  Comparative evaluation of sialylated carbohydrate antigens, KL‐6, CA19‐9 and SLX as serum markers for interstitial pneumonia , 1998, Respirology.

[33]  S. Rosselot.  Idiopathic pulmonary fibrosis. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[34]  J. Behr.  [Diagnosis of idiopathic pulmonary fibrosis]. , 2001, Pneumologie.